TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01972932

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio K+® 2 capsules orally (or via nasogastric tube)
Description: Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
Study: NCT03735953

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Retroflexion in the total colon
Description: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
Study: NCT03080493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 600mg
Description: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Packaged identical to gabapentin dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen/codeine and ibuprofen
Description: Over the counter analgesic medications

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen/codeine and ibuprofen
Description: Over the counter analgesic medications
Study: NCT02358447

Intervention type: PROCEDURE
Intervention: TKR
Description: non-navigated versus computer-navigated total knee replacement

Intervention type: PROCEDURE
Intervention: TKR
Description: non-navigated versus computer-navigated total knee replacement
Study: NCT02306590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calogen
Study: NCT03250338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idarubicin
Description: FLAG-Ida regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: FLAG-Ida regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Description: FLAG-Ida regimen
Study: NCT03448172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF-05221304
Description: a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
Study: NCT03668340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
Study: NCT03387657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study: NCT02751619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
Study: NCT02822833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node mapping
Description: Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
Study: NCT00892814

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation
Description: 40 Gy/15 fractions, 3 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast irradiation
Description: 40 Gy/15 fractions, 3 weeks
Study: NCT02661061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
Study: NCT03292614

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the postoperative refraction
Description: The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)
Study: NCT02242019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia LUNULA
Description: The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
Study: NCT00559143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular Pacing (DDD(R)- BiV)
Description: Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biventricular Pacing (DDD(R)- BiV)
Description: Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
Study: NCT02394119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
Study: NCT02371876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONYX PLUS Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
Study: NCT00532727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 every 3 weeks for six cycles (18 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100mg/m2 every 3 weeks for six cycles (18 weeks)
Study: NCT02168777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used.
Study: NCT03307837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: Local administration during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local administration during surgery
Study: NCT01744483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC ETT
Description: Placement of a PVC-cuffed ETT in the setting of emergent intubation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUC ETT
Description: Placement of a PUC-cuffed ETT in the setting of emergent intubation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUC-CASS ETT
Description: Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
Study: NCT00708474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoFit™ Porous Tissue Matrix™
Description: Bone void filler
Study: NCT01569698

Intervention type: PROCEDURE
Intervention: acute extra renal replacement therapy
Description: usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
Study: NCT02800915

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service innovation with focus on multidisciplinary collaboration
Description: The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service innovation with focus on multidisciplinary collaboration
Description: The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
Study: NCT00428012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy
Description: 8 weekly individual counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: 8 weekly individual counseling sessions
Study: NCT02461056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
Study: NCT02306590

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03968068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Procedure
Description: Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning
Description: Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
Study: NCT03967912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE UP
Description: Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
Study: NCT01531101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual psychodynamic psychotherapy
Description: Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual psychodynamic psychotherapy
Description: Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
Study: NCT03924115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmedial Psychoeducational Program to improve adherence full or partial (PS)
Description: Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmedial Psychoeducational Program to improve adherence full or partial (PS)
Description: Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.
Study: NCT04537598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine patient controlled analgesia
Description: 30 patients will receive PCA only for postoperative analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae plane block
Description: 30 patients will receive continuous ESPB for postoperative analgesia
Study: NCT04426435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: honey based (HB) syrup
Description: honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: honey based (HB) syrup
Description: honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO).
Study: NCT04192864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingually based triangular flap
Description: A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccally based triangular flap
Description: The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
Study: NCT02264262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiologic maneuvers
Description: Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
Study: NCT02484989

Intervention type: OTHER
Intervention: Surviellance card
Study: NCT01013142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221 (Dose Group 1)
Description: i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 (Dose Group 1)
Description: i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221 (Dose Group 2)
Description: i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 (Dose Group 2)
Description: i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
Study: NCT02461056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
Study: NCT03236129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-reg depleted DLI
Description: The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard DLI
Description: The patients in this arm benefit of a standard DLI.
Study: NCT04428528

Intervention type: DEVICE
Intervention: Photoacoustics Imaging System
Description: Characterizing breast masses for photoacoustic markers measurements
Study: NCT01013142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221 (Dose Group 3)
Description: i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 (Dose Group 3)
Description: i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour